Literature DB >> 2231891

Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results.

D F Paulson1, J W Moul, P J Walther.   

Abstract

A total of 441 stage T1-2N0M0 and 11 stage T1-2N0M0 cancer patients with an elevated acid phosphatase level only, and 18 stage T1-2N+M0 cancer patients underwent radical prostatectomy. Analysis of the 441 stage T1-2N0M0 cancer patients demonstrated that failure and survival were a function of the disease being organ-confined, specimen-confined or margin-positive, with 10-year failure rates of 12, 30 and 60%, respectively. Of the patients with positive margins 44 were and 79 were not irradiated postoperatively. Postoperative radiation produced no survival advantage. No difference in interval to failure or of survival could be identified between 105 patients whose disease was diagnosed by transurethral resection and 328 who had a palpable abnormality. Eleven patients had negative bone and node findings but they had an elevated acid phosphatase level. All 8 patients not treated with immediate androgen deprivation failed within 36 months.

Entities:  

Mesh:

Year:  1990        PMID: 2231891     DOI: 10.1016/s0022-5347(17)39686-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

Review 1.  [Organ-limited prostate cancer with positive resection margins. Importance of adjuvant radiation therapy].

Authors:  D Porres; D Pfister; B Brehmer; A Heidenreich
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

2.  Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.

Authors:  Robert J Lechleider; Philip M Arlen; Kwong-Yok Tsang; Seth M Steinberg; Junko Yokokawa; Vittore Cereda; Kevin Camphausen; Jeffrey Schlom; William L Dahut; James L Gulley
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

Review 3.  Evaluating radical prostatectomy specimens: therapeutic and prognostic importance.

Authors:  D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

Review 4.  Localised carcinoma of the prostate: a paradigm of uncertainty.

Authors:  S S Sandhu; A V Kaisary
Journal:  Postgrad Med J       Date:  1997-11       Impact factor: 2.401

5.  The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer.

Authors:  Xinchun Zhou; Thomas J Lawrence; Zhi He; Charles R Pound; Jinghe Mao; Steven A Bigler
Journal:  Exp Mol Pathol       Date:  2011-11-11       Impact factor: 3.362

6.  Management of prostate cancer in port harcourt, Nigeria: changing patterns.

Authors:  On Ekeke; Oe Amusan; N Eke
Journal:  J West Afr Coll Surg       Date:  2012-07

7.  Addressing the needs of the high-risk prostate cancer patient.

Authors:  Leonard G Gomella
Journal:  Rev Urol       Date:  2005

Review 8.  Adjuvant radiation therapy after radical prostatectomy: when is it indicated?

Authors:  Stephen M Graham; Jeffrey M Holzbeierlein
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

Review 9.  Cancer of the prostate.

Authors:  D P Dearnaley
Journal:  BMJ       Date:  1994-03-19

10.  Multiple transrectal ultrasound-guided biopsies for the detection of prostate cancer and determination of tumor volume, grade, and seminal vesicle invasion.

Authors:  M Norberg; L Holmberg; C Busch; M Häggman; L Egevad; A Magnusson
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.